0001193125-26-232533
SEC filingPersonalis, Inc. announced that CMS expanded Medicare coverage for its NeXT Personal test to monitor treatment response in certain breast cancer patients.
The Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for Personalis, Inc.'s NeXT Personal test. The expanded coverage includes monitoring treatment response to neoadjuvant therapy for patients diagnosed with Stage II-III Triple-Negative Breast Cancer or HER2-positive breast cancer. This regulatory development could broaden the addressable patient population for the test, though the filing does not provide revenue estimates or specific financial impact.